

IP in Healthcare 2016

Tuesday 17th May

The Royal Society of Chemistry, Burlington House, London

Wednesday 29th June

Scottish Lifesciences Association, Edinburgh

The Conference is free to attend and will achieve 4 CPD hours

Programme Outline

8.45am – 9.30am

Registration and Breakfast

9.30am – 9.35am

Welcome

9.35am – 10.05am

The CRISPR IP Landscape

Clustered regularly interspaced short palindromic repeat (CRISPR) systems are present in some bacteria as part of a protective system against foreign DNA (such as viral DNA). Following invasion by a virus, a portion of the viral DNA is incorporated in the space between two CRISPRs, providing a form of 'memory'. Following subsequent invasion, the CRISPR system recognises the virus and produces an enzyme, Cas9, to cut up the viral genetic material. The adaption of CRISPR systems as a tool kit to find, cut and replace DNA at a specific location in eukaryotes has resulted in a major breakthrough in gene-editing technology and has various applications in healthcare.

This session will take you through the CRISPR IP landscape and will delve into some of the patentability issues arising in this area.



Speakers: Catherine Coombes, Senior Patent Attorney and Kate Taylor, Partner

Cath's portfolio encompasses a wide range of biological subject matter including: biotechnology, life sciences, molecular biology, food technology, enzymology, diagnostics & therapeutics, immunology, plant sciences, stem cells and biopharmaceuticals.

Kate handles a diverse portfolio of technologies in the life sciences and biopharmaceutical fields, including antibody and peptide therapeutics, diagnostic and therapeutic targets, SNPs, antisense nucleic acids and GMOs.

10.05am – 10.35am

Pain for Pfizer but are the UK Patents Courts increasingly pro-patentee?

We shall consider the key trends in the last 12 months of pharmaceutical litigation with a review of the Patents Court's treatment of infringement and validity of Swiss form claims, plausibility and expectation of success.

Speaker: Rachel Fetches, Partner

Rachel is an intellectual property litigation partner at HGF and has worked with clients across a broad range of sectors including, life sciences, chemicals, food and beverage, aviation, media and telecommunications industries.



10.35am – 11.15am

How to construct an IP Portfolio

IP for companies in the healthcare sector: How to construct an IP portfolio to protect the company's programmes and maximise the value for the company, both from a commercial and investment perspective, based on Redx Pharma's experience with HGF since 2010.

Speaker: Derek Lindsay, Director and COO, Redx Pharma Plc

Dr Derek Lindsay is a Director and COO of Redx Pharma plc, he joined full-time in 2012, after being a Director and co-founder of the business since 2007. Previously, he was Director of Innovation of pharmaceutical industry consortium Britest Ltd, from 2006 to 2012. Prior to that Derek was R&D Director of Avecia Pharmaceutical Products and had held a series of Management roles in a career spanning 30 years; working in R&D, Process Development and Hazards at Avecia and its predecessor businesses, Zeneca and ICI, which he joined in 1988, after initially working in R&D at BP from 1985. Derek graduated from the University of Strathclyde, Glasgow, UK in



1982 with a B.Sc. (Hons) Degree in Applied Chemistry and in 1985 he attained his Ph.D. in Chemistry from the same University.

11.15 – 11.45am

Break

11.45am – 12.15pm

Kit Kat, Dairy Milk andinhalers?

Companies in the Healthcare Sector are constantly looking at ways to add value to their IP portfolios. Once patents have expired registered trade marks and designs can be essential in maintaining a competitive advantage. Delivery devices, inhalers, shapes of tablets and colours have all been protected by companies in this sector to a varying degree of success. This session will explore the best strategies the healthcare sector can adopt to best position itself. Surprisingly lessons may well need to be learnt from the confectionery sector...



Speaker: Martyn Fish, Partner and Head of HGF Law

Martyn advises healthcare companies on IP issues with a focus on trade mark, design and patent disputes. In recent years he has advised clients in the sector on the validity and enforceability of “non-traditional” trade marks and designs and their use in relation to pharmaceuticals and medical devices.

Convergence Panel Discussion

12.15pm – 12.35pm

Wearable Technology in Healthcare

Wearable devices involve the convergence of wireless communication, sensor technology, processors and graphical user interfaces. Some innovators may settle for patenting small but significant improvements to a previously known wearable system, but this could be missing a great commercial opportunity to patent an emergent feature arising from the convergence of the previously well-known technologies. For example, can innovations be found in more efficient protocols to communicate data in real-time from the wearable device to storage or to processing nodes upstream? Can solutions be found to better protect confidential user information in transit, to authenticate a user of the wearable device or to more efficiently distribute data processing tasks that perhaps utilise big data? Can the



gaming aspects of wearable devices be protected by circumventing the statutory exclusions to patentability? In a crowded healthcare wearables marketplace, how can intellectual property be leveraged to stay ahead of competitors by thinking differently? The potential rewards are vast.

Speaker: Dr Susan Keston, Patent Director

Susan has invaluable experience in drafting and prosecuting a portion of the worldwide patent portfolio for a highly successful UK-based multinational semiconductor and software tools company, which specialises in low-power Reduced Instruction Set Computing and System-on-Chip technology.

Susan's clients benefit from her strong technical expertise, keen analytical skills and commercially-focused advice. She has had the benefit of working directly and independently with numerous inspirational inventors on cutting-edge technology.

12.35pm – 12.55pm

3D Printing

3D printing, or additive manufacturing, is a process in which objects are made by fusing or depositing materials in layers to produce a 3D object. These materials generally include plastics, metals, ceramics, powders, liquids or even living cells. 3D printing applications in healthcare can be divided into four main categories: i) inorganic surgical products, such as prosthetics, implants, and anatomical models; ii) organic products, such as tissues and organs; iii) drug delivery and dosage forms; and iv) pharmaceutical research for drug discovery.

Each of these categories presents opportunities for revolutionising the healthcare industry and with these opportunities come very real threats to the protection of intellectual property rights. These threats have been likened to those faced by the entertainment industry with the advent of digital media, where traditional copyright enforcement strategies proved impractical. Digital files for 3D printing can be shared and disseminated in much the same way as digital media files. This session will review some of these opportunities and threats by drawing parallels with the entertainment industry. We will discuss some of the challenges that companies are likely to face as a result of the changing landscape this technology will bring. We will also discuss some strategies that innovative companies should consider to improve their position.

Speaker: Jason Lessard, Patent Director

Before entering the patent profession, Jason spent five years in technical sales at a multinational manufacturer of plastic injection moulding equipment in Luxembourg and the UK. He is a European Patent, Trade Mark & Design Attorney, and a



Chartered UK Patent Attorney and has successfully completed the USPTO Patent Bar Exam. Jason's commercial experience shapes his approach to advising clients; Jason delivers commercially-focused outcomes that add real value to client's businesses.

12.55pm – 1.15pm

Synthetic Biology

Synthetic biology combines the disciplines of biology and engineering has been named one of the eight great British technologies of the future. Concerns have been raised though about patents in this area making broad claims and stifling innovation. In addition the convergence of different technologies raises issues about different types of protection e.g. protecting software. It is also interesting to look at how open innovation and open source materials moving the area forward and how far we should be thinking about the application of the rules on the licensing of “standards” in synthetic biology.



Speaker: Janet Knowles, Partner

Janet has over 25 years' experience of dealing with the full range of IP rights, from patents to trade marks and related contracts. She specialises particularly in IP transactions in the science and technology fields. She has worked for many years in the healthcare sector from advising the Department of Health on its "Framework and Guidance on the Management of Intellectual Property in the NHS" to advising multinational pharmaceutical/life sciences companies on clinical trials, licensing, manufacturing and many other agreements. Janet is a Registered Technology Transfer Practitioner and one of a limited number of UK IP licensing professionals recommended by the international guide IAM 1000 - Guide to the World's Patent Practitioners (2015) and an MIP IP Star.

1.15pm – 1.30pm

Discussion

1.30pm

Lunch

About HGF's Healthcare Team

The HGF Healthcare team provides professional expertise and commercially focused advice to business leaders and decision makers in healthcare fields of biotechnology, pharmaceuticals and medical technologies. The firm has in-depth knowledge of the sector, and the experience to provide you with high quality and commercially focused advice in relation to the protection of your IP rights.

The team offers the full range of IP services including:

- IP strategy and advice
- Patent and trade mark procurement
- IP portfolio management
- Freedom-to-operate advice and opinions
- IP due diligence assessments and opinions
- Supplementary protection certificates (SPCs) and data exclusivity advice
- IP licences and agreements
- IP disputes management and litigation

The healthcare team works across the spectrum of organisations in the sector including universities, research organisations, spin outs and start-ups, SME's, generics companies and the dominant global pharmaceutical and medical companies. Our client base continues to develop and grow by recommendation.

The firm are also active participants in Medilink, AstraZeneca BioHub, PraxisUnico, BioCity Glasgow and the Sheffield City Region LEP Healthcare Technologies Sector Group. We also attend MEDTEC UK, BIO and Arab Health and provide regular speakers for C5 events.